Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

University of Toronto

$86,200.00

Next generation reagents for mass cytometry and imaging mass cytometry

EF 2023-24

Résumé
The purpose of this project is to develop better tools to help scientists in biology and the biomedical area study biological samples. Mass cytometry is a technology developed in Canada and manufactured by Fluidigm Canada in Markham ON that enables these scientists to measure and quantify many biomarkers simultaneously on cells and issue samples. Biomarkers are proteins and other biomolecules expressed on the surface of cells or inside the cells. They convey information about cell type, behavior and function as well as the disease state of a cell. Mass cytometry employs reagents based on antibodies labeled with heavy metal isotopes to detect proteins and other biomarkers expressed on individual cells. In mass cytometry, the cells are injected into the plasma torch of an atomic mass spectrometer, where the cells are vaporized, atomized and ionized to generate a cloud of the metal ions that were attached to each cell. These ions are then analyzed by mass spectrometry. Mass cytometry enables one to examine individual cells at high throughput (up to 1000 cells/sec). Its greatest strength is that it can simultaneously measure many more biomarkers per cell than flow cytometry, which employs fluorescent reagents. In current technology, one can measure ~50 biomarkers per cell at 500 to 1000 cells per second. We propose to create new reagents that will increase this number to more than 80 biomarkers per cell. To identify proteins expressed at very low levels, we will create a different set of reagents that will increase signal intensity by 10 to 100 times. This new technology will enhance our ability to study biological and disease processes, and may in the future enhance early diagnosis of disease.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
566946-2021
Name nom
Winnik, Mitchell MA
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2021
Award amount
86200
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Bioanalytical chemistry
Research subject en
Chimie analytique
Research subject fr
Chimie bioanalytique
Application title
Next generation reagents for mass cytometry and imaging mass cytometry
Keyword
antibody conjugation; biomarker detection; lanthanide nanoparticles; mass cytometry; metal-chelating polymers
Application summary
The purpose of this project is to develop better tools to help scientists in biology and the biomedical area study biological samples. Mass cytometry is a technology developed in Canada and manufactured by Fluidigm Canada in Markham ON that enables these scientists to measure and quantify many biomarkers simultaneously on cells and issue samples. Biomarkers are proteins and other biomolecules expressed on the surface of cells or inside the cells. They convey information about cell type, behavior and function as well as the disease state of a cell. Mass cytometry employs reagents based on antibodies labeled with heavy metal isotopes to detect proteins and other biomarkers expressed on individual cells. In mass cytometry, the cells are injected into the plasma torch of an atomic mass spectrometer, where the cells are vaporized, atomized and ionized to generate a cloud of the metal ions that were attached to each cell. These ions are then analyzed by mass spectrometry. Mass cytometry enables one to examine individual cells at high throughput (up to 1000 cells/sec). Its greatest strength is that it can simultaneously measure many more biomarkers per cell than flow cytometry, which employs fluorescent reagents. In current technology, one can measure ~50 biomarkers per cell at 500 to 1000 cells per second. We propose to create new reagents that will increase this number to more than 80 biomarkers per cell. To identify proteins expressed at very low levels, we will create a different set of reagents that will increase signal intensity by 10 to 100 times. This new technology will enhance our ability to study biological and disease processes, and may in the future enhance early diagnosis of disease.